Source-grounded facts extracted from Turn Therapeutics Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Turn Therapeutics Inc. reported three months ended March 31, 2026 results: net income $ (970,972 ), EPS $ (0.03 ).
“Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunological therapies for dermatologic conditions, today reported financial results for the three months ended March 31, 2026”
Turn Therapeutics Inc. reported the year ended December 31, 2025 results: net income NET LOSS $ (3,194,080 ), EPS Basic and diluted net loss per common share $ (0.12 ).
“liability 380,442 - Amortization of deferred offering cost (496,948 ) - Interest income 29,583 28,709 Other income 176,520 - Total other income 2,664,568 28,709 NET LOSS $ (3,194,080 ) $ (1,768,415 ) Basic and diluted net loss per common share $ (0.12 ) $ (0.07 ) Weighted-average common shares outstanding, basic and diluted 27,716,045 26,643,432 Turn”
Turn Therapeutics Inc. issued shares of Common Stock with an aggregate value of $1.2 million of common stock to Avenue Venture Opportunities Fund II, L.P..
“the Company issued to the Lender shares of Common Stock with an aggregate value of $1.2 million, with the exact number of shares calculated by dividing (i) $1.2 million by (ii) the volume-weighted average price of the Common Stock, determined for the five (5) consecutive trading days ending on the last trading day immediately preceding the Closing Date (the “Equity Grant”).”
Turn Therapeutics Inc. incurred term loan of up to $25.0 million with Avenue Venture Opportunities Fund II, L.P. at greater of (x) the sum of 5.50% plus the prime rate as reported in The Wall Stre maturing October 1, 2029.
“On March 23, 2026 (the “Closing Date”), Turn Therapeutics Inc. (the “Company”) entered into a Loan and Security Agreement (the “Loan and Security Agreement”) and a Supplement to the Loan and Security Agreement (the “Supplement” and, together with the Loan and Security Agreement, the “Loan Agreement”), with Avenue Venture Opportunities Fund II, L.P., as administrative agent, collateral agent (in such capacities, the “Agent”) and as a lender (in such capacity, together with each other lender from time to time party thereto, the “Lender”). The Loan Agreement makes available to the Company term loans in an aggregate principal amount of up to $25.0 million with (i) $7.0 million funded within one business day of the Closing Date (“Tranche 1”) and (ii) up to $8.0 million to be made available to the Company between September 1, 2026 and March 31, 2027, subject to, among other things, the Company’s achievement of specified clinical and financing milestones (“Tranche 2”).”
Turn Therapeutics Inc. entered into Loan and Security Agreement with Avenue Venture Opportunities Fund II, L.P. valued at up to $25.0 million (effective 2026-03-23).
“On March 23, 2026 (the “Closing Date”), Turn Therapeutics Inc. (the “Company”) entered into a Loan and Security Agreement (the “Loan and Security Agreement”) and a Supplement to the Loan and Security Agreement (the “Supplement” and, together with the Loan and Security Agreement, the “Loan Agreement”), with Avenue Venture Opportunities Fund II, L.P., as administrative agent, collateral agent (in such capacities, the “Agent”) and as a lender”
Turn Therapeutics Inc.: Amended and restated bylaws became effective on September 30, 2025, as previously approved by Board and stockholders (effective 2025-09-30).
“On September 30, 2025, in connection with the Direct Listing, the Company filed its amended and restated certificate of incorporation (the “Certificate of Incorporation”) with the Secretary of State of the State of Delaware, and its amended and restated bylaws (the “Bylaws”) became effective.”
Turn Therapeutics Inc.: Amended and restated certificate of incorporation filed with Delaware Secretary of State on September 30, 2025, effective upon effectiveness of the Registration Statement (effective 2025-09-30).
“On September 30, 2025, in connection with the Direct Listing, the Company filed its amended and restated certificate of incorporation (the “Certificate of Incorporation”) with the Secretary of State of the State of Delaware, and its amended and restated bylaws (the “Bylaws”) became effective.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.